Contineum Therapeutics, Inc. Logo

Contineum Therapeutics, Inc.

Clinical-stage biopharma developing oral small molecule therapies for NI&I conditions.

CTNM | US

Overview

Corporate Details

ISIN(s):
US21217B1008
LEI:
Country:
United States of America
Address:
3565 GENERAL ATOMICS COURT, SUITE 200, 92121 SAN DIEGO

Description

Contineum Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops novel, oral small molecule therapies for conditions at the intersection of neurology, inflammation, and immunology (NI&I). The company focuses on pioneering treatments that target clinically validated biological pathways to address diseases with limited therapeutic options. Its pipeline features multiple drug candidates in clinical trials. Key programs include a lysophosphatidic acid 1 (LPA1) receptor antagonist for idiopathic pulmonary fibrosis (IPF) and progressive multiple sclerosis (PrMS), and an M1 muscarinic receptor (M1R) antagonist for major depressive disorder (MDD), developed in collaboration with Janssen Pharmaceutica NV.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2024-12-15
English
4.2 MB
2024-10-30
German
1.8 MB
2024-08-14
French
0.5 MB
2024-05-22
English
2.1 MB
2024-03-10
English
3.5 MB
2024-01-15
German
1.2 MB
2023-11-20
English
5.1 MB

Full Filing History Restricted

Access to specific historical documents or filtered results is limited in the Web UI. Request access to the complete dataset.

Automate Your Workflow. Get a real-time feed of all Contineum Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Contineum Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Contineum Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

BELITE BIO, INC Logo
Clinical-stage biopharma developing therapies for retinal and metabolic diseases.
United States of America
BLTE
Benitec Biopharma Inc. Logo
A clinical-stage biotech developing genetic medicines to silence disease-causing genes.
United States of America
BNTC
BeOne Medicines Ltd. Logo
Global oncology company that discovers, develops, and delivers cancer treatments.
United States of America
ONC
BerGenBio Logo
Clinical-stage biopharma that developed selective AXL kinase inhibitors for cancer.
Norway
BGBIO
Beximco Pharmaceuticals Ltd. Logo
Manufacturer of generic drugs, APIs, and specialized products for global markets.
Bangladesh
BXP
BeyondSpring Inc. Logo
Clinical-stage biopharma company developing immuno-oncology cancer therapies.
United States of America
BYSI
BGM Group Ltd. Logo
A holding company focused on technology and biopharmaceutical manufacturing.
United States of America
BGM
Bicara Therapeutics Inc. Logo
Clinical-stage biopharma developing dual-action biologics for solid tumors.
United States of America
BCAX
BICYCLE THERAPEUTICS PLC Logo
Clinical-stage biopharma developing a novel class of bicyclic peptide medicines.
United States of America
BCYC
BIFIDO. Co. Ltd Logo
Biotechnology firm developing human-derived Bifidobacterium for various products.
South Korea
238200

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.